Novel Vaccine Delivery Systems - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB512243984

Publication Date:

December 3, 2024

Pages:

108

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Novel vaccine delivery includes formulations, technologies, methods, and systems to transfer an active pharmaceutical ingredient in the body, as desired, in order to safely accomplish its therapeutic effect.
The global market for Novel Vaccine Delivery Systems was estimated to be worth US$ 5690 million in 2023 and is forecast to a readjusted size of US$ 12080 million by 2030 with a CAGR of 10.8% during the forecast period 2024-2030
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Novel Vaccine Delivery Systems, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Novel Vaccine Delivery Systems by region & country, by Type, and by Application.
The Novel Vaccine Delivery Systems market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Novel Vaccine Delivery Systems.
麻豆原创 Segmentation
By Company
Altaris Capital Partners
Kindeva Drug Delivery
Becton
Dickinson,
Carl Zeiss Foundation
Gerresheimer AG
Corium International
Inovio Pharmaceuticals
Bioject Medical Technologies
PharmaJet
Retractable Technologies
Terumo Corporation
VAXXAS
Segment by Type:
Intradermal Delivery
Intramuscular Delivery
Others
Segment by Application
Hospitals & Clinics
Research Institutes
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Novel Vaccine Delivery Systems manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Novel Vaccine Delivery Systems in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Novel Vaccine Delivery Systems in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Novel Vaccine Delivery Systems Product Introduction
1.2 Global Novel Vaccine Delivery Systems 麻豆原创 Size Forecast
1.3 Novel Vaccine Delivery Systems 麻豆原创 Trends & Drivers
1.3.1 Novel Vaccine Delivery Systems Industry Trends
1.3.2 Novel Vaccine Delivery Systems 麻豆原创 Drivers & Opportunity
1.3.3 Novel Vaccine Delivery Systems 麻豆原创 Challenges
1.3.4 Novel Vaccine Delivery Systems 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Novel Vaccine Delivery Systems Players Revenue Ranking (2023)
2.2 Global Novel Vaccine Delivery Systems Revenue by Company (2019-2024)
2.3 Key Companies Novel Vaccine Delivery Systems Manufacturing Base Distribution and Headquarters
2.4 Key Companies Novel Vaccine Delivery Systems Product Offered
2.5 Key Companies Time to Begin Mass Production of Novel Vaccine Delivery Systems
2.6 Novel Vaccine Delivery Systems 麻豆原创 Competitive Analysis
2.6.1 Novel Vaccine Delivery Systems 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Novel Vaccine Delivery Systems Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Novel Vaccine Delivery Systems as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Intradermal Delivery
3.1.2 Intramuscular Delivery
3.1.3 Others
3.2 Global Novel Vaccine Delivery Systems Sales Value by Type
3.2.1 Global Novel Vaccine Delivery Systems Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Novel Vaccine Delivery Systems Sales Value, by Type (2019-2030)
3.2.3 Global Novel Vaccine Delivery Systems Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospitals & Clinics
4.1.2 Research Institutes
4.1.3 Others
4.2 Global Novel Vaccine Delivery Systems Sales Value by Application
4.2.1 Global Novel Vaccine Delivery Systems Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Novel Vaccine Delivery Systems Sales Value, by Application (2019-2030)
4.2.3 Global Novel Vaccine Delivery Systems Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Novel Vaccine Delivery Systems Sales Value by Region
5.1.1 Global Novel Vaccine Delivery Systems Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Novel Vaccine Delivery Systems Sales Value by Region (2019-2024)
5.1.3 Global Novel Vaccine Delivery Systems Sales Value by Region (2025-2030)
5.1.4 Global Novel Vaccine Delivery Systems Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Novel Vaccine Delivery Systems Sales Value, 2019-2030
5.2.2 North America Novel Vaccine Delivery Systems Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Novel Vaccine Delivery Systems Sales Value, 2019-2030
5.3.2 Europe Novel Vaccine Delivery Systems Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Novel Vaccine Delivery Systems Sales Value, 2019-2030
5.4.2 Asia Pacific Novel Vaccine Delivery Systems Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Novel Vaccine Delivery Systems Sales Value, 2019-2030
5.5.2 South America Novel Vaccine Delivery Systems Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Novel Vaccine Delivery Systems Sales Value, 2019-2030
5.6.2 Middle East & Africa Novel Vaccine Delivery Systems Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Novel Vaccine Delivery Systems Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Novel Vaccine Delivery Systems Sales Value
6.3 United States
6.3.1 United States Novel Vaccine Delivery Systems Sales Value, 2019-2030
6.3.2 United States Novel Vaccine Delivery Systems Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Novel Vaccine Delivery Systems Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Novel Vaccine Delivery Systems Sales Value, 2019-2030
6.4.2 Europe Novel Vaccine Delivery Systems Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Novel Vaccine Delivery Systems Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Novel Vaccine Delivery Systems Sales Value, 2019-2030
6.5.2 China Novel Vaccine Delivery Systems Sales Value by Type (%), 2023 VS 2030
6.5.3 China Novel Vaccine Delivery Systems Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Novel Vaccine Delivery Systems Sales Value, 2019-2030
6.6.2 Japan Novel Vaccine Delivery Systems Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Novel Vaccine Delivery Systems Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Novel Vaccine Delivery Systems Sales Value, 2019-2030
6.7.2 South Korea Novel Vaccine Delivery Systems Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Novel Vaccine Delivery Systems Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Novel Vaccine Delivery Systems Sales Value, 2019-2030
6.8.2 Southeast Asia Novel Vaccine Delivery Systems Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Novel Vaccine Delivery Systems Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Novel Vaccine Delivery Systems Sales Value, 2019-2030
6.9.2 India Novel Vaccine Delivery Systems Sales Value by Type (%), 2023 VS 2030
6.9.3 India Novel Vaccine Delivery Systems Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Altaris Capital Partners
7.1.1 Altaris Capital Partners Profile
7.1.2 Altaris Capital Partners Main Business
7.1.3 Altaris Capital Partners Novel Vaccine Delivery Systems Products, Services and Solutions
7.1.4 Altaris Capital Partners Novel Vaccine Delivery Systems Revenue (US$ Million) & (2019-2024)
7.1.5 Altaris Capital Partners Recent Developments
7.2 Kindeva Drug Delivery
7.2.1 Kindeva Drug Delivery Profile
7.2.2 Kindeva Drug Delivery Main Business
7.2.3 Kindeva Drug Delivery Novel Vaccine Delivery Systems Products, Services and Solutions
7.2.4 Kindeva Drug Delivery Novel Vaccine Delivery Systems Revenue (US$ Million) & (2019-2024)
7.2.5 Kindeva Drug Delivery Recent Developments
7.3 Becton
7.3.1 Becton Profile
7.3.2 Becton Main Business
7.3.3 Becton Novel Vaccine Delivery Systems Products, Services and Solutions
7.3.4 Becton Novel Vaccine Delivery Systems Revenue (US$ Million) & (2019-2024)
7.3.5 Dickinson, Recent Developments
7.4 Dickinson,
7.4.1 Dickinson, Profile
7.4.2 Dickinson, Main Business
7.4.3 Dickinson, Novel Vaccine Delivery Systems Products, Services and Solutions
7.4.4 Dickinson, Novel Vaccine Delivery Systems Revenue (US$ Million) & (2019-2024)
7.4.5 Dickinson, Recent Developments
7.5 Carl Zeiss Foundation
7.5.1 Carl Zeiss Foundation Profile
7.5.2 Carl Zeiss Foundation Main Business
7.5.3 Carl Zeiss Foundation Novel Vaccine Delivery Systems Products, Services and Solutions
7.5.4 Carl Zeiss Foundation Novel Vaccine Delivery Systems Revenue (US$ Million) & (2019-2024)
7.5.5 Carl Zeiss Foundation Recent Developments
7.6 Gerresheimer AG
7.6.1 Gerresheimer AG Profile
7.6.2 Gerresheimer AG Main Business
7.6.3 Gerresheimer AG Novel Vaccine Delivery Systems Products, Services and Solutions
7.6.4 Gerresheimer AG Novel Vaccine Delivery Systems Revenue (US$ Million) & (2019-2024)
7.6.5 Gerresheimer AG Recent Developments
7.7 Corium International
7.7.1 Corium International Profile
7.7.2 Corium International Main Business
7.7.3 Corium International Novel Vaccine Delivery Systems Products, Services and Solutions
7.7.4 Corium International Novel Vaccine Delivery Systems Revenue (US$ Million) & (2019-2024)
7.7.5 Corium International Recent Developments
7.8 Inovio Pharmaceuticals
7.8.1 Inovio Pharmaceuticals Profile
7.8.2 Inovio Pharmaceuticals Main Business
7.8.3 Inovio Pharmaceuticals Novel Vaccine Delivery Systems Products, Services and Solutions
7.8.4 Inovio Pharmaceuticals Novel Vaccine Delivery Systems Revenue (US$ Million) & (2019-2024)
7.8.5 Inovio Pharmaceuticals Recent Developments
7.9 Bioject Medical Technologies
7.9.1 Bioject Medical Technologies Profile
7.9.2 Bioject Medical Technologies Main Business
7.9.3 Bioject Medical Technologies Novel Vaccine Delivery Systems Products, Services and Solutions
7.9.4 Bioject Medical Technologies Novel Vaccine Delivery Systems Revenue (US$ Million) & (2019-2024)
7.9.5 Bioject Medical Technologies Recent Developments
7.10 PharmaJet
7.10.1 PharmaJet Profile
7.10.2 PharmaJet Main Business
7.10.3 PharmaJet Novel Vaccine Delivery Systems Products, Services and Solutions
7.10.4 PharmaJet Novel Vaccine Delivery Systems Revenue (US$ Million) & (2019-2024)
7.10.5 PharmaJet Recent Developments
7.11 Retractable Technologies
7.11.1 Retractable Technologies Profile
7.11.2 Retractable Technologies Main Business
7.11.3 Retractable Technologies Novel Vaccine Delivery Systems Products, Services and Solutions
7.11.4 Retractable Technologies Novel Vaccine Delivery Systems Revenue (US$ Million) & (2019-2024)
7.11.5 Retractable Technologies Recent Developments
7.12 Terumo Corporation
7.12.1 Terumo Corporation Profile
7.12.2 Terumo Corporation Main Business
7.12.3 Terumo Corporation Novel Vaccine Delivery Systems Products, Services and Solutions
7.12.4 Terumo Corporation Novel Vaccine Delivery Systems Revenue (US$ Million) & (2019-2024)
7.12.5 Terumo Corporation Recent Developments
7.13 VAXXAS
7.13.1 VAXXAS Profile
7.13.2 VAXXAS Main Business
7.13.3 VAXXAS Novel Vaccine Delivery Systems Products, Services and Solutions
7.13.4 VAXXAS Novel Vaccine Delivery Systems Revenue (US$ Million) & (2019-2024)
7.13.5 VAXXAS Recent Developments
8 Industry Chain Analysis
8.1 Novel Vaccine Delivery Systems Industrial Chain
8.2 Novel Vaccine Delivery Systems Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Novel Vaccine Delivery Systems Sales Model
8.5.2 Sales Channel
8.5.3 Novel Vaccine Delivery Systems Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Altaris Capital Partners
Kindeva Drug Delivery
Becton
Dickinson,
Carl Zeiss Foundation
Gerresheimer AG
Corium International
Inovio Pharmaceuticals
Bioject Medical Technologies
PharmaJet
Retractable Technologies
Terumo Corporation
VAXXAS

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.